Indications:
ARALEN is indicated for the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis.
ARALEN does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum.
Dosage and administration:
Cerebral malaria patients:
Intravenous infusion 18-24 mg/kg(60kg for those weighing more than 60kg) on day 1, 12mg/kg on day 2, and 10mg/kg on day 3.
The concentration of chloroquine phosphate was added to 10% glucose solution or 5% glucose sodium chloride injection 500ml every 0.5g, and the intravenous infusion rate was 12 to 20 drops per minute.
Drug interactions:
If you use other drugs or over the counter products at the same time, the effects of Chloroquine Phosphate Injection may change. This may increase your risk for side-effects or cause your drug not to work properly. Tell your doctor about all the drugs, vitamins, and herbal supplements you are using, so that you doctor can help you prevent or manage drug interactions. Chloroquine Phosphate Injection may interact with the following drugs and products:
Arsenic trioxide
Cisapride
Dofetilide
Erythromycin
Fluconazole
Levofloxacin
Storage:
Do not store above 25°C.